Umbralisib R-enantiomer is primarily used in the development and research of targeted cancer therapies. It functions as a potent and selective inhibitor of PI3K-delta, an enzyme involved in the growth and survival of certain cancer cells. This compound is particularly studied for its potential in treating hematologic malignancies, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), including subtypes like follicular lymphoma and marginal zone lymphoma. Its application focuses on disrupting signaling pathways that promote cancer cell proliferation, offering a promising approach for precision medicine in oncology. Additionally, it is being explored for its potential to enhance the efficacy of other cancer treatments when used in combination therapies and for its effects on immune-related processes involving white blood cells.